Ruling by DC Circuit Court of Appeals Provides CSL the Right to Challenge CBP’s Plasma Ban

Statement attributable to Greg Boss, Executive Vice President - Legal, and CSL Limited Group General Counsel.

11 May 2022

We are encouraged by the United States Court of Appeals for the District of Columbia Circuit’s ruling that plasma companies have the legal right to challenge the Customs and Border Protection (CBP) ban on plasma donation by Mexican nationals entering the country on a B1/B2 visa. We are also pleased that the Court of Appeals’ decision acknowledges the importance of Mexican plasma donors in providing this critical resource necessary to manufacture life-saving, plasma-derived therapies. 

We await further instruction from the United States District Court and will continue to challenge the plasma ban and secure a more stable plasma supply for the hundreds of thousands of patients dependent on plasma-derived therapies.

About CSL Plasma 
CSL Plasma, operates one of the world’s largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in the U.S., Europe and China. Headquartered in Boca Raton, Florida, CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. Plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 25,000 people. For more information about CSL Plasma, visit

About CSL
CSL (ASX: CSL; USOTC:CSLLY) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 100 countries and employs more than 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For more information, visit